Charlottesville, VA, United States of America

Guoquan Wang

This inventor holds 18 USPTO granted patents and 2 published patent applications, plus 2 CIPO patents and 5 EPO patents. Top assignees: Pgxhealth, LLC, Dogwood Pharmaceuticals, Inc., Lewis and Clark Pharmaceuticals, Inc.. Active years: 2008-2017.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Guoquan Wang. Retrieved from https://idiyas.com/inventor/guoquan-wang

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 18 (Patent Applications = 2)

% Patents Active = 27.8

CIPO Patents = 2 (Patent Applications = 1)

EPO Patents = 5 (Patent Applications = 3)

Average Co-Inventor Count = 2.9

ph-index = 6

Forward Citations = 191(Granted Patents)

Location History:

Charlottesville, VA (US) (2008 - 2017)
Crozet, VA (US) (2017)

Company Filing History:

Dogwood Pharmaceuticals, Inc.

patents

3 out of 3

Lewis and Clark Pharmaceuticals, Inc.

patents

4. 2 out of 5

Adenosine Therapeutics, LLC

patents

5. 1 out of 1

Dogwoof Pharmaceuticals, Inc.

Forest Laboratories Holdings Limited

patents

8. 1 out of 1,044

University of Virginia Patent Foundation

patents

9. 1 out of 834,513

Other

patents

where one patent can have more than one assignee

Years Active: 2008-2017

Loading Chart...

18 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9822141 - [object Object] (2017-11-21),

2. 9593118 - [object Object] (2017-03-14),

3. 9067963 - [object Object] (2015-06-30),

4. 8501941 - Methods for the synthesis of unsymmetrical cycloakyl substituted xanthines (2013-08-06),

5. 8420813 - Methods for the synthesis of unsymmetrical cycloalkyl substituted xanthines (2013-04-16),

6. 8349848 - [object Object] (2013-01-08),

7. 8258142 - Substituted 8-[6-amino-3-pyridyl]xanthines (2012-09-04),

8. 8193200 - Antagonists of A2B adenosine receptors for treatment of inflammatory bowel disease (2012-06-05),

9. 8153628 - Pyrazolyl substituted xanthines (2012-04-10),

10. 7884100 - Substituted 8-[6-amino-3-pyridyl]xanthines (2011-02-08),

11. 7875608 - Substituted 8-[6-amino-3pyridyl]xanthines (2011-01-25),

12. 7732455 - Substituted 8-heteroaryl xanthines (2010-06-08),

13. 7618962 - Pyrazolyl substituted xanthines (2009-11-17),

14. 7601723 - Pyridyl substituted xanthines (2009-10-13),

15. 7598379 - Methods for the synthesis of unsymmetrical cycloalkyl substituted xanthines (2009-10-06),

Title: Guoquan Wang: Innovator in Pharmaceutical Chemistry

Introduction

Guoquan Wang is a prominent inventor based in Charlottesville, VA, known for his significant contributions to pharmaceutical chemistry. With a total of 18 patents to his name, he has made remarkable advancements in the field of adenosine receptor research.

Latest Patents

His latest patents include innovative compounds such as N-alkyl 2-(disubstituted)alkynyladenosine-5'-uronamides and derivatives, which serve as selective agonists of adenosine receptors (ARs). These compounds and their pharmaceutical compositions are poised to be valuable agents in medical applications. Another notable patent involves xanthine-substituted alkynyl carbamates and reverse carbamates, which act as selective antagonists of adenosine receptors. These inventions also hold promise as pharmaceutical agents.

Career Highlights

Throughout his career, Guoquan Wang has worked with several companies, including Pgxhealth, LLC and Lewis and Clark Pharmaceuticals, Inc. His work has significantly impacted the development of new therapeutic agents.

Collaborations

He has collaborated with notable professionals in the field, including Robert Douglas Thompson and Jayson Michael Rieger, further enhancing the scope of his research and innovations.

Conclusion

Guoquan Wang's contributions to pharmaceutical chemistry through his patents and collaborations highlight his role as a leading inventor in the industry. His work continues to influence the development of new medical therapies.

Profile summary based on public USPTO records.